Drugs / MT-2301
last change Sep 2015 re-read 2 minutes ago

MT-2301

Developed for
haemophilus infectious disease
Investigated by
Tanabe Pharma Corporation

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02140047 Apr 2014 → Jan 2015 haemophilus infectious disease Tanabe Pharma Corporation Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MT-2301 “Exploratory Clinical Study of MT-2301NCT02140047